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 Many drugs that are available in the overseas market have not yet been 
approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan. A study of 
the top 100 drugs by sales in 2004 shows a 2.5-year gap between the launch dates in the 
UK/US and Japan [1]. Of a total of 398 new chemical entities that were approved in 
either the US, EU, or Japan between 1999 and 2007, 325 (82%) were approved in the 
US, 314 (79%) in the EU, but only 220 (55%) were approved in Japan [2]. This gap, or 
so-called drug lag, differs among drugs with different therapeutic indications. Drugs 
against infectious diseases have short lags, whereas those for the treatment of the 
central nervous system diseases have much longer lags [2,3]. The lag prevents Japanese 
patients with neurological diseases from accessing these drugs at the same time as 
patients in other developed nations access them. Further, it may even delay the 
progress of clinical research in Japan. 
 We analysed Japanese and UK data regarding the approval of new neurological 
drugs. The Japanese data were obtained from the website of the Japan Pharmaceutical 
Information Center (JAPIC), from the section on new drug approval 
(http://www.shinsahoukokusho.jp/), which included a review report of all new molecular 
entities and new biologics approved in Japan between June 1999 and April 2010. The 
UK data were obtained from the Electronic Medicines Compendium 
(http://www.medicines.org.uk/emc/). We selected the UK because according to the 
International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) guidelines [4], the regulation of drugs is 
harmonised between Japan and the UK; in addition, the UK, like Japan, provides a 




 We defined approval lag as the difference between the date of approval in 
Japan and the date of first authorization in the UK. Japan’s review time was defined as 
the time between the date of application for approval and the date of approval. 
 During the 11 years from June 1999 and April 2010, 22 new neurological drugs 
were introduced in Japan (Table). Of these, 20 were already available in the UK when 
they were approved in Japan, with a median lag of 65 months. The median review time 
(from application for approval to approval) of these 20 drugs was 22 months. Only 
clobazam and sumatriptan succinate were first approved in Japan and then in the UK, 
with lag times of 22 months and 20 months, respectively. Sixteen neurological drugs 
were available in the UK but not in Japan.  
 Few studies have quantified Japan’s drug lag in terms of therapeutic 
indications. Hirai et al. [3] studied a data set of all new molecular entities and new 
biologics approved between January 2000 and December 2006 in Japan, the US, and the 
EU and showed that Japan’s median delay in development time was 35.5 months. 
Among drugs from different therapeutic areas, those for central nervous system 
diseases showed the longest delay of 53.5 months [3]. Our analysis, focusing on the 
introduction of new neurological drugs, showed that Japan lags behind the UK by 65 
months. 
 Drug lag consists of the delay in development time (i.e. up to application for 
approval) as well as review time. The median review time of 22 months observed in our 
study was longer than the European Medicines Agency (EMA) review time of 13.5 
months [5]. However, this 9-month difference cannot explain the overall lag of 65 
months. Although we could not precisely identify the development time, the above data 
show that most of the lag is presumably due to delays in development, not review. In 
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contrast to these 22 drugs already approved in Japan, 16 (42%) of 38 drugs are 
approved in the UK but not in Japan, showing the so-called absolute drug lag [2]. 
 The data presented in this study confirm that Japan’s drug lag in the case of 
neurological drugs is quite substantial and keeps Japanese patients from the benefits of 
new treatments. The general public in Japan hopes that the simultaneous development 
of drugs on a global scale and improvements of the regulatory system would effectively 
reduce the delay, but the following problems make this goal seem difficult to achieve. 
First, the difference in the prevalence of some neurological disorders, e.g., multiple 
sclerosis, between Japan and the UK makes it difficult to recruit sufficient numbers of 
patients for clinical trials in Japan. Second, language problems among Japanese 
participants in multinational trials delay the development of new drugs in Japan. Third, 
the high cost and underperformance of clinical trials in Japan [2,3] may have a 
significant effect on drug lag.  
 Our results underscore the necessity for further analysis into the causes of the 
lag, with close attention not only to the role played by the Japanese regulatory 
authority but also to that played by the pharmaceutical companies and citizens. 
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Table  Japanese and UK data regarding the approval neurological drugs     
Generic name (proprietary) Indication 
Approval 
Application
Approval Date Lag 
Review 
Time 
    Japan Japan UK (Months) Japan 
Donepezil Alzheimer disease Jul 98 Oct 99 Feb 97 32 14 
Galantamine Alzheimer disease   Sep 00   
Memantine Alzheimer disease   May 02   
Rivastigmine Alzheimer disease   Dec 98   
Clobazam Epilepsy Mar 97 Mar 00 Jan 02 -22 36 
Fosphenytoin Epilepsy   Jul 04   
Gabapentin Epilepsy Apr 04 Jul 06 Jun 05 14 27 
Lamotrigine Epilepsy Dec 05 Oct 08 Aug 97 134 34 
Levetiracetam Epilepsy   Sep 00   
Oxcarbazepine Epilepsy   Nov 01   
Rufinamide Epilepsy   Jan 07   
Topiramate Epilepsy Jul 04 Jul 07 Jul 95 145 36 
Vigabatrin Epilepsy   Jan 01   
Clopidogrel Ischaemic stroke Feb 04 Jan 06 Jul 98 90 23 
Almotriptan Migraine   Oct 00   
Eletriptan Migraine Jun 00 Apr 02 Feb 01 14 21 
Frovatriptan Migraine   Oct 02   
Naratriptan Migraine Apr 06 Jan 08 Apr 02 69 21 
Rizatriptan Migraine Nov 01 Jul 03 Jun 98 61 20 
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Sumatriptan Migraine May 01 Apr 03 May 96 83 23 
Sumatriptan succinate Migraine Aug 00 Jun 01 Feb 03 -20 11 
Zolmitriptan Migraine Mar 00 Jun 01 Jun 00 12 15 
Glatiramer acetate Multiple sclerosis   Apr 03   
Interferon beta-1a (Avonex) Multiple sclerosis Jun 03 Jul 06 Mar 97 113 37 
Interferon beta-1a (Rebif) Multiple sclerosis   May 98   
Interferon beta-1b Multiple sclerosis Sep 99 Sep 00 Nov 95 58 12 
Natalizumab Multiple sclerosis   Jun 06   
Piracetam Myoclonus NA Sep 99 Dec 92 81 NA
Pregabalin Neuropathic Pain NA Apr 10 Jul 04 69 NA
Cabergoline Parkinson disease NA Jun 99 Feb 96 40 NA
Entacapone Parkinson disease Apr 05 Jan 07 Sep 98 100 21 
Pramipexole Parkinson disease Dec 01 Oct 03 Feb 98 68 22 
Rasagiline Parkinson disease   Feb 05   
Ropinirole Parkinson disease Dec 02 Oct 06 Jan 02 57 46 
Rotigotine Parkinson disease   Feb 06   
Alglucosidase alfa Pompe disease Apr 05 Apr 07 Mar 06 13 24 
Ziconotide Severe chronic pain   Feb 05   
Zinc acetate Wilson disease May 06 Jan 08 Oct 04 39 21 
NA: Not available 
